Celator Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013090)
◆英語タイトル:Celator Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013090
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:26
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Celator Pharmaceuticals Inc (Celator) is a clinical-stage biopharmaceutical company that develops and distributes therapies for treating cancer disease. The company’s products include cytarabine and daunorubicin liposomal formulation, irinotecan HCI and floxuridine and hydrophobic docetaxel prodrug nanoparticle formulation. Its proprietary technology platform, CombiPlex enables the rational design and rapid evaluation of optimized combinations, incorporating traditional chemotherapies and molecularly targeted agents to deliver enhanced anti-cancer activity. The current development pipeline includes novel, clinical-stage combination products and drug discovery programs based on the CombiPlex platform. Celator is headquartered in Ewing, New Jersey, the US.

Celator Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Celator Pharma Raises US$39 Million In Venture Financing 10
Celator Pharma Secures US$3 Million In Venture Financing 11
Partnerships 12
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 12
Celator Pharma Extends Research Agreement With Cephalon 13
Equity Offering 14
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 14
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 16
Acquisition 18
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 18
Celator Pharmaceuticals Inc – Key Competitors 20
Celator Pharmaceuticals Inc – Key Employees 21
Celator Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
May 10, 2016: Celator Pharmaceuticals Announces First Quarter 2016 Financial Results and Business Update 23
Mar 21, 2016: Celator Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2015 Financial Results 24
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Celator Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Celator Pharma Raises US$39 Million In Venture Financing 10
Celator Pharma Secures US$3 Million In Venture Financing 11
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 12
Celator Pharma Extends Research Agreement With Cephalon 13
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 14
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 16
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 18
Celator Pharmaceuticals Inc, Key Competitors 20
Celator Pharmaceuticals Inc, Key Employees 21
Celator Pharmaceuticals Inc, Subsidiaries 22

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Celator Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析(Celator Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆